Mobile website
Archive > Volume 33 Issue 5 > 2026,33(5):494-499. DOI:10.3872/j.issn.1007-385X.2026.05.003 Prev Next
Basic Research
Preparation of Trop2-ECD_HPF fusion nanoparticles and their immunotherapeutic effects against triple-negative breast cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To construct a Trop2-ECD_HPF fusion nanoparticle vaccine and evaluate its immunogenicity and antitumor activity against triple-negative breast cancer (TNBC). Methods: The Trop2-ECD_HPF nanoparticle vaccine was constructed, and subsequently expressed and purified in 293F cells. The purity and homogeneity of the vaccine were verified by size exclusion chromatography and transmission electron microscopy. The vaccine was formulated with aluminum adjuvant and used to immunize female BALB/c mice. The Trop2-specific antibody titers in serum were detected by enzyme-linked immunosorbent assay (ELISA), and the inhibitory effect of the vaccine on the 4T1-Trop2 tumor model was evaluated. Results: The Trop2-ECD_HPF nanoparticles had an average diameter of approximately 20 nm and exhibited high assembly efficiency and high purity. The vaccine effectively induced high- titer Trop2-specific antibodies in mice, with titers reaching 10? at week 6 in the vaccine group, significantly higher than those in the adjuvant control group (P < 0.000 1). In animal studies, mice in the vaccine group exhibited a significant reduction in tumor volume (tumor inhibition rate: 38.6%) and a marked delay in tumor growth rate (P < 0.001), demonstrating strong antitumor efficacy. Conclusion: The Trop2-ECD_HPF fusion nanoparticle vaccine effectively induced a specific humoral immune response and significantly inhibited the growth of TNBC, providing experimental evidence for the development of Trop2-targeted nanoparticle vaccines.
Keywords:
Project Supported:
Clc Number:
